Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Rebalancing can affect how withdrawal rates hold up over time. Learn factors that influence stability and how to adjust portfolio rules.
24,481 articlesNovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
OpenAI unveils GPT-5.4, its most capable enterprise AI to date, combining advanced reasoning, coding, and autonomous ...
A sweeping real-world study of roughly 600,000 GLP-1 users finds cravings for cigarettes, alcohol, and other addictio...
Specialized Medicare Advantage plans targeting chronic conditions and low-income subscribers accounted for the majori...
Ethereum hovers near a pivotal price band that previously sparked a major move. On-chain activity is rising as trader...
The Bank Policy Institute is weighing legal action against the OCC to challenge national trust charters for crypto an...
Investors weigh Amazon's Zoox-related progress against UPS's strategic shifts while oil volatility stirs the market. ...
Intel remains the Dow's most shorted stock as fresh data show rising short interest amid continued cash burn in the f...
As layoffs linger in tech and startups recalibrate, candidates confront the toughest interview question: why were you...
Tesla stock has slid about 18% from its December peak as deliveries declined and autonomy safety metrics raise questi...
In 2026, AI budgets surge while pilots fade. A four‑pillar playbook separates winners from the rest, focusing on data...
Leveraged ETFs like TQQQ and QLD promise amplified Nasdaq-100 exposure, but they come with unique risks and timing re...